TRCT
BBLG

Tower Research Capital (TRC)’s Bone Biologics BBLG Stock Holding History

Tower Research Capital (TRC)’s Portfolio BBLG Stock Details BBLG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.54K Buy
4,126
+747
+22% +$1.03K ﹤0.01% 4186
2025
Q4 		$4.9K Buy
3,379
+1,915
+131% +$3.82K ﹤0.01% 4168
2025
Q3 		$4.08K Buy
1,464
+1,264
+632% +$3.2K ﹤0.01% 4405
2025
Q2 		$806 Sell
200
-104
-34% -$481 ﹤0.01% 4936
2025
Q1 		$1.46K Sell
304
-261
-46% -$1.51K ﹤0.01% 4705
2024
Q4 		$3.18K Buy
565
+267
+90% +$2.2K ﹤0.01% 4694
2024
Q3 		$3.8K Sell
298
-667
-69% -$6.32K ﹤0.01% 4771
2024
Q2 		$7.06K Buy
965
+257
+36% +$2.54K ﹤0.01% 4503
2024
Q1 		$9.05K Buy
708
+504
+247% +$9.84K ﹤0.01% 3909
2023
Q4 		$5.54K Buy
204
+65
+47% +$1.62K ﹤0.01% 4828
2023
Q3 		$4.75K Buy
139
+13
+10% +$644 ﹤0.01% 4818
2023
Q2 		$8.64K Buy
126
+120
+2,000% +$31.4K ﹤0.01% 4401
2023
Q1 		$2K Hold
6
– – ﹤0.01% 5309
2022
Q4 		$2K Buy
6
+1
+20% +$563 ﹤0.01% 5327
2022
Q3 		$8K Buy
5
+1
+25% +$1.87K ﹤0.01% 4761
2022
Q2 		$9K Buy
+4
New +$10.6K ﹤0.01% 4536

Other funds holding BBLG

SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Tower Research Capital (TRC)'s BBLG Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Bone Biologics (BBLG) stake by 22% in Q1 2026, buying an estimated $1.03K and bringing the position to 4,126 shares worth $4.54K. The position accounts for ﹤0.01% of the portfolio, ranked #4186.

Tower Research Capital (TRC) first reported a position in BBLG in Q2 2022 and has held it in 16 quarters since. The position peaked at $9.05K in Q1 2024. 3 funds tracked by Wall St. Rank hold BBLG as of Q1 2026.

  • Tower Research Capital (TRC) held 4,126 shares of Bone Biologics worth $4.54K as of Q1 2026.
  • Tower Research Capital (TRC) bought 747 Bone Biologics shares in Q1 2026, an estimated $1.03K.
  • Bone Biologics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #4186 holding.
  • Tower Research Capital (TRC) first reported a position in Bone Biologics in Q2 2022 and has held it in 16 quarters since.
  • Tower Research Capital (TRC)'s Bone Biologics position peaked at $9.05K in Q1 2024.
  • 3 funds tracked by Wall St. Rank held Bone Biologics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.